Literature DB >> 30111239

Intracellular displacement of p53 using transactivation domain (p53 TAD) specific nanobodies.

Anneleen Steels1, Adriaan Verhelle1, Olivier Zwaenepoel1, Jan Gettemans1.   

Abstract

The tumor suppressor p53 is of crucial importance in the prevention of cellular transformation. In the presence of cellular stress signals, the negative feedback loop between p53 and Mdm2, its main negative regulator, is disrupted, which results in the activation and stabilization of p53. Via a complex interplay between both transcription-dependent and - independent functions of p53, the cell will go through transient cell cycle arrest, cellular senescence or apoptosis. However, it remains difficult to completely fathom the mechanisms behind p53 regulation and its responses, considering the presence of multiple layers involved in fine-tuning them. In order to take the next step forward, novel research tools are urgently needed. We have developed single-domain antibodies, also known as nanobodies, that specifically bind with the N-terminal transactivation domain of wild type p53, but that leave the function of p53 as a transcriptional transactivator intact. When the nanobodies are equipped with a mitochondrial-outer-membrane (MOM)-tag, we can capture p53 at the mitochondria. This nanobody-induced mitochondrial delocalization of p53 is, in specific cases, associated with a decrease in cell viability and with morphological changes in the mitochondria. These findings underpin the potential of nanobodies as bona fide research tools to explore protein function and to unravel their biochemical pathways.

Entities:  

Keywords:  VHH; cancer; cell death; intrabody; mitochondria; nanobodies; single-domain-antibody; the tumor suppressor p53

Mesh:

Substances:

Year:  2018        PMID: 30111239      PMCID: PMC6204812          DOI: 10.1080/19420862.2018.1502025

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  73 in total

1.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

2.  Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain.

Authors:  Grzegorz M Popowicz; Anna Czarna; Tad A Holak
Journal:  Cell Cycle       Date:  2008-05-27       Impact factor: 4.534

Review 3.  Nanobodies: natural single-domain antibodies.

Authors:  Serge Muyldermans
Journal:  Annu Rev Biochem       Date:  2013-03-13       Impact factor: 23.643

4.  A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus.

Authors:  L D Mayo; D B Donner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

5.  WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization.

Authors:  York Tomita; Natasha Marchenko; Susan Erster; Alice Nemajerova; Alexander Dehner; Christian Klein; Hongguang Pan; Horst Kessler; Petr Pancoska; Ute M Moll
Journal:  J Biol Chem       Date:  2006-01-26       Impact factor: 5.157

6.  Regulation of autophagy by cytoplasmic p53.

Authors:  Ezgi Tasdemir; M Chiara Maiuri; Lorenzo Galluzzi; Ilio Vitale; Mojgan Djavaheri-Mergny; Marcello D'Amelio; Alfredo Criollo; Eugenia Morselli; Changlian Zhu; Francis Harper; Ulf Nannmark; Chrysanthi Samara; Paolo Pinton; José Miguel Vicencio; Rosa Carnuccio; Ute M Moll; Frank Madeo; Patrizia Paterlini-Brechot; Rosario Rizzuto; Gyorgy Szabadkai; Gérard Pierron; Klas Blomgren; Nektarios Tavernarakis; Patrice Codogno; Francesco Cecconi; Guido Kroemer
Journal:  Nat Cell Biol       Date:  2008-05-04       Impact factor: 28.824

7.  Human TAFII31 protein is a transcriptional coactivator of the p53 protein.

Authors:  H Lu; A J Levine
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-23       Impact factor: 11.205

8.  Unravelling mechanisms of p53-mediated tumour suppression.

Authors:  Kathryn T Bieging; Stephano Spano Mello; Laura D Attardi
Journal:  Nat Rev Cancer       Date:  2014-04-17       Impact factor: 60.716

9.  A promiscuous biotin ligase fusion protein identifies proximal and interacting proteins in mammalian cells.

Authors:  Kyle J Roux; Dae In Kim; Manfred Raida; Brian Burke
Journal:  J Cell Biol       Date:  2012-03-12       Impact factor: 10.539

Review 10.  The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches.

Authors:  Andreas C Joerger; Alan R Fersht
Journal:  Annu Rev Biochem       Date:  2016-05-04       Impact factor: 23.643

View more
  5 in total

Review 1.  Exploring cellular biochemistry with nanobodies.

Authors:  Ross W Cheloha; Thibault J Harmand; Charlotte Wijne; Thomas U Schwartz; Hidde L Ploegh
Journal:  J Biol Chem       Date:  2020-08-31       Impact factor: 5.157

Review 2.  Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology.

Authors:  Congcong Zhang; Rina M Ötjengerdes; Julian Roewe; Rebeca Mejias; Andrea L J Marschall
Journal:  BioDrugs       Date:  2020-08       Impact factor: 5.807

3.  Nanobody-directed targeting of optogenetic tools to study signaling in the primary cilium.

Authors:  Jan N Hansen; Fabian Kaiser; Christina Klausen; Birthe Stüven; Raymond Chong; Wolfgang Bönigk; David U Mick; Andreas Möglich; Nathalie Jurisch-Yaksi; Florian I Schmidt; Dagmar Wachten
Journal:  Elife       Date:  2020-06-24       Impact factor: 8.140

Review 4.  An Inside Job: Applications of Intracellular Single Domain Antibodies.

Authors:  Eline Soetens; Marlies Ballegeer; Xavier Saelens
Journal:  Biomolecules       Date:  2020-12-12

Review 5.  Recent findings on the role of wild-type and mutant p53 in cancer development and therapy.

Authors:  Mehregan Babamohamadi; Esmaeil Babaei; Burhan Ahmed Salih; Mahshid Babamohammadi; Hewa Jalal Azeez; Goran Othman
Journal:  Front Mol Biosci       Date:  2022-09-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.